Gene therapy: credibility or curse?
Keywords:
Gene therapy, strategies, advantages, disadvantages, germline, in vivo, ex vivoAbstract
Background: Gene therapy is a promising therapeutic approach that involves introducing functional genetic material into defective or diseased cells to treat or prevent disease. Recent advances have led to significant success in managing inherited disorders such as cystic fibrosis, alpha-1 antitrypsin deficiency, hemophilia, beta-thalassemia, and sickle cell disease, and have also shown potential in treating cancers and infectious diseases, including HIV. Several gene therapy products have received regulatory approval for clinical use; however, concerns regarding their long-term efficacy and safety remain. Methodology: This review summarizes the current status of gene therapy by discussing major therapeutic approaches, including ex vivo and in vivo gene delivery, genome editing, somatic gene therapy, and germline gene therapy. It also examines the clinical outcomes of approved gene therapies and evaluates their associated safety challenges. Results and Discussion: Advances in gene therapy have demonstrated encouraging clinical outcomes, particularly for inherited genetic disorders. Somatic gene therapy has shown promising efficacy and an acceptable safety profile in approved clinical applications. In contrast, germline gene therapy still faces substantial technical, ethical, and safety concerns, limiting its clinical translation despite its potential to prevent hereditary diseases. Conclusion: Gene therapy represents a transformative strategy for treating genetic and acquired diseases. While somatic gene therapy has become a viable clinical option, germline gene therapy requires further technological refinement and rigorous safety evaluation before widespread clinical application. Continued research is expected to improve the safety, efficacy, and therapeutic potential of gene-based interventions.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Ameena Ahmed, Mrinmoy Pratim Chetia, Satyabrat Sarma

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
In submitting an article to Journal of Applied Pharmacognosy and Phytochemistry (JOAPP) I certify that:
- I am authorized by my co-authors to enter into these arrangements.
- I warrant, on behalf of myself and my co-authors, that:
- the article is original, has not been formally published in any other peer-reviewed journal, is not under consideration by any other journal and does not infringe any existing copyright or any other third party rights;
- I am/we are the sole author(s) of the article and have full authority to enter into this agreement and in granting rights to JOAPR are not in breach of any other obligation;
- the article contains nothing that is unlawful, libellous, or which would, if published, constitute a breach of contract or of confidence or of commitment given to secrecy;
- I/we have taken due care to ensure the integrity of the article. To my/our - and currently accepted scientific - knowledge all statements contained in it purporting to be facts are true and any formula or instruction contained in the article will not, if followed accurately, cause any injury, illness or damage to the user.
- I, and all co-authors, agree that the article, if editorially accepted for publication, shall be licensed under the Creative Commons Attribution-NonCommercial 4.0 International License
- I, and all co-authors, agree that, if the article is editorially accepted for publication in Journal of Applied Pharmaceutical Research (JOAPR) data included in the article shall be made available under the Creative Commons 1.0 Public Domain Dedication waiver, unless otherwise stated. For the avoidance of doubt it is stated that sections 1, 2, and 3 of this license agreement shall apply and prevail.



